{'fraction_non_alphanumeric': 0.03899721448467967, 'fraction_numerical': 0.033426183844011144, 'mean_word_length': 4.988888888888889, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Transurethral plasmokinetic resection and vaporization is a new method of treatment of prostatic adenoma].

Clinical efficacy and safety ofplasmakinetic resection and vaporization were studied in 28 patients with prostatic adenoma (mean age 68 years, mean size of the prostate 65 cm3). Complaints by IPSS scale, quality of life index, results of uroflowmetry and prostatic ultrasonography were assessed before surgery (transurethral plasmakinetic resection and prostatic vaporization) and 1, 3, 6 and 12 months after it. Twenty-five and 15 patients after 6 and 12 months after the operation were examined with the following results: IPSS was 6 scores, on the average (22.5 scores before the operation), quality of life index--3.1 (5.3 scores). Qmax was in 3 months 20 ml/s, on the average (7.5 ml/s), residual urine was under 35 ml (130.7 ml). Pilot results point to high clinical efficacy and safety of plasmakinetic resection and vaporization in patients with prostatic adenoma. Therefore, further studies of the method and accumulation of clinical experience are necessary.